Tacrolimus (FK506) is a potent immunosuppressant widely used to prevent rejection following organ transplantation. In this study, we employed a photonic crystal microarray-based competitive assay to measure tacrolimus blood concentrations, facilitating bedside and at-home monitoring for transplant recipients. The photonic crystal microarray technology offers flexibility, cost-effectiveness, and high efficiency. When integrated with a portable fluorescence intensity detector, it enables rapid and quantitative analysis. By fabricating the photonic crystal microarray and leveraging the photonic crystal bandgap enhancement effect to amplify the fluorescence intensity of probe molecules, the detection sensitivity is significantly improved. The photonic crystal microarray demonstrated a remarkable fluorescence enhancement factor of 17.2-fold compared to conventional substrates, significantly improving the sensitivity of tacrolimus detection. The optimized system achieved a detection limit of 0.4 ng·mL−1, enabling rapid and accurate quantification of tacrolimus concentration within 20 min.
- Article type
- Year
- Co-author
Open Access
Research Article
Issue
Open Access
Original Article
Issue
The aim of this study was to develop and validate a fatty liver index based on laboratory data (FLI‐L) and a fatty liver index based on both physical examination and laboratory data (FLI‐PL) in the hope of providing a more convenient, accurate, and quantitative method for the diagnosis of fatty liver disease.
The study included data for 12,391 patients obtained from the Third Medical Center of Chinese PLA General Hospital. FLI‐L and FLI‐PL were developed using binary logistic regression analysis. The diagnostic performance of the FLI‐L and FLI‐PL was evaluated using the area under the receiver‐operating characteristic curve (AUC‐ROC) with sensitivity, specificity, and positive and negative likelihood ratios. FLI‐L and FLI‐PL were subsequently validated in 3170 patients from the same hospital.
The AUC‐ROC for FLI‐L was 0.876 with a cut‐off value of 55.03. Sensitivity was 81.35 and specificity was 78.28, with an accuracy of 79.99% for discriminating between patients with and without fatty liver disease. The AUC‐ROC for FLI‐PL was 0.902 with a cut‐off value of 20.51. Sensitivity was 85.10 and specificity was 79.64. FLI‐PL classified 91.65% of patients correctly.
FLI‐L and FLI‐PL is used for simple and accurate quantitative diagnosis of fatty liver disease. This study provides evidence to support the use of this index in clinical management.
京公网安备11010802044758号